- Q1 2024 Medicure Inc Earnings Call TranscriptMay 29, 2024C$1.03Earnings
- Q4 2023 Medicure Inc Earnings Call TranscriptApr 09, 2024C$1.08 (+1.89%)Earnings
- Q3 2023 Medicure Inc Earnings Call TranscriptNov 22, 2023C$1.45 (-3.33%)Earnings
- Q2 2023 Medicure Inc Earnings Call TranscriptJul 31, 2023C$1.46 (+4.29%)Earnings
- Q1 2023 Medicure Inc Earnings Call TranscriptMay 29, 2023C$1.24 (+12.73%)Earnings
- Q4 2022 Medicure Inc Earnings Call TranscriptApr 10, 2023C$1.16 (+1.75%)Earnings
- Q3 2022 Medicure Inc Earnings Call TranscriptNov 25, 2022C$1.09 (-0.91%)Earnings
- Q2 2022 Medicure Inc Earnings Call TranscriptAug 25, 2022C$1.03 (-6.36%)Earnings
- Q1 2022 Medicure Inc Earnings Call TranscriptMay 31, 2022C$1.44 (+20.00%)Earnings
- Q4 2021 Medicure Inc Earnings Call TranscriptApr 28, 2022C$0.95 (+14.46%)Earnings
- Q3 2021 Medicure Inc Earnings Call TranscriptNov 23, 2021C$1.16 (+10.48%)Earnings
- Q2 2021 Medicure Inc Earnings Call TranscriptAug 30, 2021C$1.13Earnings
- Q1 2021 Medicure Inc Earnings Call TranscriptMay 11, 2021C$1.2 (-20.00%)Earnings
- Q3 2020 Medicure Inc Earnings Call TranscriptNov 12, 2020C$0.78 (-2.50%)Earnings
- Q2 2020 Medicure Inc Earnings Call TranscriptAug 12, 2020C$1.01Earnings
- Q1 2020 Medicure Inc Earnings Call TranscriptMay 13, 2020C$1.08 (-11.48%)Earnings
- Q4 2019 Medicure Inc Earnings Call TranscriptApr 16, 2020C$1.85 (-23.24%)Earnings
- Q3 2019 Medicure Inc Earnings Call TranscriptNov 27, 2019C$4.83 (-3.98%)Earnings
- Q2 2019 Medicure Inc Earnings Call TranscriptAug 09, 2019C$4.61Earnings
- Q1 2019 Medicure Inc Earnings Call TranscriptMay 28, 2019C$5 (-16.53%)Earnings
- Full Year 2018 Medicure Inc Earnings Call TranscriptApr 30, 2019C$6.3 (+4.65%)Earnings
Q1 2019 Medicure Inc Earnings Call Transcript
Welcome to the first quarter 2019 conference call. My name is Paulette, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded.
I will now turn the call over to Dr. Friesen. You may begin.
Thanks, Paulette, and good morning to all on the call. We appreciate your interest and participation on today's call. Joining me is the CFO, James Kinley; and Vice President Commercial, Kevin Taylor.
The number of patients using AGGRASTAT continues to increase although modestly to now just at 65%, but with pricing pressures, the net income is lower for this quarter. The revenue for the quarter ended March 31, 2019, from AGGRASTAT was $4.8 million, which was lower than Q1 2018, which was $6.1 million.
We also experienced negative earnings, substantially because of the significant investment in the market push for both ZYPITAMAG and ReDS. The adjusted EBITDA for Q1 was $1.7 million compared to -- negative $1.7
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)